CA2633825A1 - Comprimes de lansoprazole se desintegrant oralement - Google Patents
Comprimes de lansoprazole se desintegrant oralement Download PDFInfo
- Publication number
- CA2633825A1 CA2633825A1 CA002633825A CA2633825A CA2633825A1 CA 2633825 A1 CA2633825 A1 CA 2633825A1 CA 002633825 A CA002633825 A CA 002633825A CA 2633825 A CA2633825 A CA 2633825A CA 2633825 A1 CA2633825 A1 CA 2633825A1
- Authority
- CA
- Canada
- Prior art keywords
- sub
- tablet
- orally disintegrating
- tablets
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000006191 orally-disintegrating tablet Substances 0.000 title claims abstract description 116
- 229960003174 lansoprazole Drugs 0.000 title claims description 46
- MJIHNNLFOKEZEW-UHFFFAOYSA-N lansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-UHFFFAOYSA-N 0.000 title claims description 46
- 239000003826 tablet Substances 0.000 claims abstract description 193
- 229940079593 drug Drugs 0.000 claims abstract description 157
- 239000003814 drug Substances 0.000 claims abstract description 157
- 239000010410 layer Substances 0.000 claims description 105
- 239000002253 acid Substances 0.000 claims description 85
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 62
- 239000002702 enteric coating Substances 0.000 claims description 54
- 238000009505 enteric coating Methods 0.000 claims description 54
- 239000011247 coating layer Substances 0.000 claims description 44
- 230000000087 stabilizing effect Effects 0.000 claims description 42
- 239000003381 stabilizer Substances 0.000 claims description 36
- 239000000203 mixture Substances 0.000 claims description 33
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 22
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 22
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 22
- 238000009826 distribution Methods 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 21
- 150000001556 benzimidazoles Chemical class 0.000 claims description 20
- 229960003943 hypromellose Drugs 0.000 claims description 20
- 239000000454 talc Substances 0.000 claims description 20
- 229910052623 talc Inorganic materials 0.000 claims description 20
- 239000003795 chemical substances by application Substances 0.000 claims description 17
- 229920001577 copolymer Polymers 0.000 claims description 17
- 239000004014 plasticizer Substances 0.000 claims description 16
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 15
- 235000000346 sugar Nutrition 0.000 claims description 15
- 239000011248 coating agent Substances 0.000 claims description 13
- 238000000576 coating method Methods 0.000 claims description 12
- 239000002245 particle Substances 0.000 claims description 12
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 10
- 238000007906 compression Methods 0.000 claims description 10
- 230000006835 compression Effects 0.000 claims description 10
- 229920003145 methacrylic acid copolymer Polymers 0.000 claims description 10
- 229940117841 methacrylic acid copolymer Drugs 0.000 claims description 10
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 claims description 9
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical group O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims description 7
- 229920002261 Corn starch Polymers 0.000 claims description 6
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims description 6
- 125000005395 methacrylic acid group Chemical group 0.000 claims description 6
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
- 235000019759 Maize starch Nutrition 0.000 claims description 5
- 239000001913 cellulose Substances 0.000 claims description 5
- 229960001021 lactose monohydrate Drugs 0.000 claims description 5
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 claims description 5
- 239000001095 magnesium carbonate Substances 0.000 claims description 5
- 229910000021 magnesium carbonate Inorganic materials 0.000 claims description 5
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 claims description 5
- 238000005507 spraying Methods 0.000 claims description 5
- 239000004408 titanium dioxide Substances 0.000 claims description 5
- 229920002472 Starch Polymers 0.000 claims description 4
- 229920002678 cellulose Polymers 0.000 claims description 4
- 239000007891 compressed tablet Substances 0.000 claims description 4
- 238000005336 cracking Methods 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 239000000377 silicon dioxide Substances 0.000 claims description 4
- 239000008107 starch Substances 0.000 claims description 4
- 235000019698 starch Nutrition 0.000 claims description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical group [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 3
- 238000001125 extrusion Methods 0.000 claims description 3
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 2
- 239000008119 colloidal silica Substances 0.000 claims description 2
- 239000000654 additive Substances 0.000 claims 2
- 230000000996 additive effect Effects 0.000 claims 2
- 235000010980 cellulose Nutrition 0.000 claims 2
- 235000019814 powdered cellulose Nutrition 0.000 claims 1
- 229920003124 powdered cellulose Polymers 0.000 claims 1
- 239000011162 core material Substances 0.000 description 74
- 239000000463 material Substances 0.000 description 23
- 239000006185 dispersion Substances 0.000 description 17
- 238000009472 formulation Methods 0.000 description 10
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 9
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 9
- IQPSEEYGBUAQFF-UHFFFAOYSA-N Pantoprazole Chemical compound COC1=CC=NC(CS(=O)C=2NC3=CC=C(OC(F)F)C=C3N=2)=C1OC IQPSEEYGBUAQFF-UHFFFAOYSA-N 0.000 description 9
- 230000002378 acidificating effect Effects 0.000 description 9
- SUBDBMMJDZJVOS-DEOSSOPVSA-N esomeprazole Chemical compound C([S@](=O)C1=NC2=CC=C(C=C2N1)OC)C1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-DEOSSOPVSA-N 0.000 description 9
- 229960004770 esomeprazole Drugs 0.000 description 9
- 229960000381 omeprazole Drugs 0.000 description 9
- 229960005019 pantoprazole Drugs 0.000 description 9
- 229920000642 polymer Polymers 0.000 description 9
- YREYEVIYCVEVJK-UHFFFAOYSA-N rabeprazole Chemical compound COCCCOC1=CC=NC(CS(=O)C=2NC3=CC=CC=C3N=2)=C1C YREYEVIYCVEVJK-UHFFFAOYSA-N 0.000 description 9
- 229960004157 rabeprazole Drugs 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 238000004090 dissolution Methods 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 239000008188 pellet Substances 0.000 description 6
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 5
- 239000012055 enteric layer Substances 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 229920003134 Eudragit® polymer Polymers 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 210000002249 digestive system Anatomy 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- GDCRSXZBSIRSFR-UHFFFAOYSA-N ethyl prop-2-enoate;2-methylprop-2-enoic acid Chemical compound CC(=C)C(O)=O.CCOC(=O)C=C GDCRSXZBSIRSFR-UHFFFAOYSA-N 0.000 description 4
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- 239000001069 triethyl citrate Substances 0.000 description 4
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 4
- 235000013769 triethyl citrate Nutrition 0.000 description 4
- 229910002012 Aerosil® Inorganic materials 0.000 description 3
- 108010011485 Aspartame Proteins 0.000 description 3
- 229920003135 Eudragit® L 100-55 Polymers 0.000 description 3
- 241000220223 Fragaria Species 0.000 description 3
- 235000016623 Fragaria vesca Nutrition 0.000 description 3
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 3
- 239000000605 aspartame Substances 0.000 description 3
- 229960003438 aspartame Drugs 0.000 description 3
- 235000010357 aspartame Nutrition 0.000 description 3
- 239000007884 disintegrant Substances 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- SWXVUIWOUIDPGS-UHFFFAOYSA-N diacetone alcohol Natural products CC(=O)CC(C)(C)O SWXVUIWOUIDPGS-UHFFFAOYSA-N 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 238000007922 dissolution test Methods 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- -1 i.e. Polymers 0.000 description 2
- 229960001375 lactose Drugs 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 150000004682 monohydrates Chemical class 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 230000009747 swallowing Effects 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 244000024675 Eruca sativa Species 0.000 description 1
- 235000014755 Eruca sativa Nutrition 0.000 description 1
- 229920003138 Eudragit® L 30 D-55 Polymers 0.000 description 1
- 229920003141 Eudragit® S 100 Polymers 0.000 description 1
- 239000008122 artificial sweetener Substances 0.000 description 1
- 235000021311 artificial sweeteners Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 239000012738 dissolution medium Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- XACKNLSZYYIACO-DJLDLDEBSA-N edoxudine Chemical compound O=C1NC(=O)C(CC)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XACKNLSZYYIACO-DJLDLDEBSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000009475 tablet pressing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/314,656 | 2005-12-20 | ||
| PCT/US2005/046296 WO2007078271A2 (fr) | 2005-12-20 | 2005-12-20 | Comprimes a desintegration orale de lansoprazole |
| EP05257891.1 | 2005-12-20 | ||
| US11/314,656 US20070141151A1 (en) | 2005-12-20 | 2005-12-20 | Lansoprazole orally disintegrating tablets |
| USPCT/US05/46296 | 2005-12-20 | ||
| EP05257891A EP1813275A1 (fr) | 2005-12-20 | 2005-12-20 | Comprime oral desintegrable de lansoprazole |
| PCT/US2006/048961 WO2007075980A2 (fr) | 2005-12-20 | 2006-12-20 | Comprimes de lansoprazole se desintegrant oralement |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2633825A1 true CA2633825A1 (fr) | 2007-07-05 |
Family
ID=38218650
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002633825A Abandoned CA2633825A1 (fr) | 2005-12-20 | 2006-12-20 | Comprimes de lansoprazole se desintegrant oralement |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1962844A2 (fr) |
| JP (1) | JP2009524592A (fr) |
| CA (1) | CA2633825A1 (fr) |
| IL (1) | IL191923A0 (fr) |
| WO (1) | WO2007075980A2 (fr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2044929A1 (fr) * | 2007-10-04 | 2009-04-08 | Laboratorios del Dr. Esteve S.A. | Comprimés oraux à désintégration rapide |
| WO2009113090A2 (fr) * | 2008-01-17 | 2009-09-17 | Alkem Laboratories Ltd. | Procédé de préparation d’une formule orale d’un médicament à base de benzimidazole sensible à l’acide |
| TWI441658B (zh) | 2008-03-11 | 2014-06-21 | Takeda Pharmaceutical | 口腔崩解固體製劑 |
| CN101507718B (zh) * | 2009-03-03 | 2011-05-04 | 张登科 | 雷贝拉唑钠肠溶口崩片及其制备方法 |
| FR2949061B1 (fr) * | 2009-08-12 | 2013-04-19 | Debregeas Et Associes Pharma | Microgranules flottants |
| WO2011111027A2 (fr) * | 2010-03-11 | 2011-09-15 | Dexcel Pharma Technologies Ltd. | Formulation de comprimé oral dispersible à libération retardée |
| WO2012111024A1 (fr) * | 2011-02-18 | 2012-08-23 | Suven Nishtaa Pharma Pvt Ltd | Compositions pharmaceutiques de dexlansoprazole |
| JP2020055755A (ja) * | 2018-09-28 | 2020-04-09 | 日本ケミファ株式会社 | 腸溶性製剤 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9402431D0 (sv) * | 1994-07-08 | 1994-07-08 | Astra Ab | New tablet formulation |
| ES2094694B1 (es) * | 1995-02-01 | 1997-12-16 | Esteve Quimica Sa | Nueva formulacion farmaceuticamente estable de un compuesto de bencimidazol y su proceso de obtencion. |
| ATE261303T1 (de) * | 1995-09-21 | 2004-03-15 | Pharma Pass Ii Llc | Neues ein säureempfindliches benzimidazol enthaltendes mittel und verfahren zu dessen herstellung |
| SE9600070D0 (sv) * | 1996-01-08 | 1996-01-08 | Astra Ab | New oral pharmaceutical dosage forms |
| DK2263660T3 (en) * | 1998-05-18 | 2018-01-02 | Takeda Pharmaceuticals Co | Orally disintegrating tablets. |
| US20050214371A1 (en) * | 2004-03-03 | 2005-09-29 | Simona Di Capua | Stable pharmaceutical composition comprising an acid labile drug |
-
2006
- 2006-12-20 CA CA002633825A patent/CA2633825A1/fr not_active Abandoned
- 2006-12-20 EP EP06848925A patent/EP1962844A2/fr not_active Withdrawn
- 2006-12-20 WO PCT/US2006/048961 patent/WO2007075980A2/fr active Application Filing
- 2006-12-20 JP JP2008547591A patent/JP2009524592A/ja active Pending
-
2008
- 2008-06-03 IL IL191923A patent/IL191923A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL191923A0 (en) | 2009-08-03 |
| EP1962844A2 (fr) | 2008-09-03 |
| WO2007075980A8 (fr) | 2008-07-17 |
| WO2007075980A3 (fr) | 2008-02-21 |
| WO2007075980A2 (fr) | 2007-07-05 |
| JP2009524592A (ja) | 2009-07-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11452689B2 (en) | Taste-masked pharmaceutical compositions | |
| US10952971B2 (en) | Taste-masked pharmaceutical compositions with gastrosoluble pore-formers | |
| US20070141151A1 (en) | Lansoprazole orally disintegrating tablets | |
| Chen et al. | Tablets of multi-unit pellet system for controlled drug delivery | |
| EP1809251B1 (fr) | Compositions pharmaceutiques multiparticulaires au gout masqué contenant les particules de noyaux et une membrane coacervée par les solvants | |
| AU784613B2 (en) | Taste masked pharmaceutical particles | |
| CA2630235A1 (fr) | Comprimes a desintegration orale de lansoprazole | |
| EP1813275A1 (fr) | Comprime oral desintegrable de lansoprazole | |
| TW200803871A (en) | New combination dosage form | |
| CA2633825A1 (fr) | Comprimes de lansoprazole se desintegrant oralement | |
| US20090202630A1 (en) | Orally disintegrating tablet compositions of ranitidine and methods of manufacture |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |